---
document_datetime: 2024-11-12 17:34:34
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/elocta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: elocta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.7039136
conversion_datetime: 2025-12-17 08:00:23.323287
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## ELOCTA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0058            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 11/11/2024                          |                                             | Annex II and PL                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0057             | B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation                                                                                                                                                                                                                                                                                         | 09/10/2024   | n/a   |      |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|------|-----------------------------------|
| N/0055              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                            | 08/10/2024   | n/a   |      |                                   |
| IB/0053             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                         | 10/09/2024   | n/a   |      |                                   |
| IA/0054/G           | This was an application for a group of variations. A.z - Administrative change - Other variation B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with | 22/07/2024   | n/a   |      |                                   |
| IB/0052/G           | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                        | 15/07/2024   |       | SmPC |                                   |
| PSUSA/10451 /202306 | Periodic Safety Update EU Single assessment - efmoroctocog alfa                                                                                                                                                                                                                                                                                                                                             | 11/01/2024   | n/a   |      | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0050             | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)                                                                                                                             | 18/04/2023   | n/a   |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10451 /202206 | Periodic Safety Update EU Single assessment - efmoroctocog alfa                                                                                                                                                                                                                                                                                               | 12/01/2023   | n/a   | PRAC Recommendation - maintenance |
| IA/0049/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 18/11/2022   | n/a   |                                   |
| IB/0047             | B.z - Quality Change - Other variation                                                                                                                                                                                                                                                                                                                        | 27/06/2022   | n/a   |                                   |
| PSUSA/10451 /202106 | Periodic Safety Update EU Single assessment - efmoroctocog alfa                                                                                                                                                                                                                                                                                               | 13/01/2022   | n/a   | PRAC Recommendation - maintenance |
| IA/0045/G           | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                        | 29/06/2021   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                            |            |            |             |                                                                                                                                                                                                                                                                         |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0043             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                          | 05/05/2021 | n/a        |             |                                                                                                                                                                                                                                                                         |
| IA/0044/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 14/04/2021 | n/a        |             |                                                                                                                                                                                                                                                                         |
| PSUSA/10451 /202006 | Periodic Safety Update EU Single assessment - efmoroctocog alfa                                                                                                                                                                                                                                                                                                                                                                                       | 14/01/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |
| II/0039             | Update of sections 4.8, 5.1 of the SmPC to include the results of study 997HA306 in previously untreated patients which have previously been assessed as an Article 46 paediatric submission and renewal (EMEA/H/C/003964/R/0036). Additionally, minor changes are included in the Package Leaflet.                                                                                                                                                   | 14/01/2021 | 06/01/2022 | SmPC and PL | Section 5.1 of the SmPC has been updated to include the results of study 997HA306 in previously untreated patients (PUPs). Section 4.8 of the SmPC has been updated to include 'Papular rash' and 'device related thrombosis' as common adverse drug reactions in PUPs. |

<div style=\"page-break-after: always\"></div>

|             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                             |            |            |                        |                                                                                                                                                                                                                                                                      |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0041     | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                  | 14/09/2020 | n/a        |                        |                                                                                                                                                                                                                                                                      |
| R/0036      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                       | 25/06/2020 | 19/08/2020 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Elocta in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0038     | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                  | 24/06/2020 | n/a        |                        |                                                                                                                                                                                                                                                                      |
| IAIN/0037/G | This was an application for a group of variations. B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking B.IV.1.b - Change of a measuring or administration | 27/03/2020 | n/a        |                        |                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| PSUSA/10451 /201906   | Periodic Safety Update EU Single assessment - efmoroctocog alfa                                                                                                                                                                   | 16/01/2020   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0034             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                | 26/08/2019   | n/a        |             |                                                                                                                                                                                                                                                                                                                                     |
| IB/0032               | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) | 10/07/2019   | n/a        |             |                                                                                                                                                                                                                                                                                                                                     |
| II/0030               | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                 | 06/06/2019   | 09/07/2019 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                     |
| PSUSA/10451 /201812   | Periodic Safety Update EU Single assessment - efmoroctocog alfa                                                                                                                                                                   | 14/06/2019   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                   |
| PSUSA/10451 /201806   | Periodic Safety Update EU Single assessment - efmoroctocog alfa                                                                                                                                                                   | 17/01/2019   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                   |
| II/0026               | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                 | 13/12/2018   | 09/07/2019 | SmPC        | The MAH submitted the results of the study 8HA01EXT evaluating the long-term safety and efficacy of ELOCTA in the prevention and treatment of bleeding episodes and for perioperative management. Section 4.8 and 5.1 were updated to update information regarding prophylaxis regimens, paediatric population, and immunogenicity. |
| X/0021                | Annex I_2.(c) Change or addition of a new                                                                                                                                                                                         | 20/09/2018   | 07/12/2018 | SmPC, Annex |                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                     | strength/potency                                                                                                                                                                                                                                                                                                            |            |     | II, Labelling and PL   |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|-----------------------------------|
| IA/0029             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                            | 27/09/2018 | n/a |                        |                                   |
| PSUSA/10451 /201712 | Periodic Safety Update EU Single assessment - efmoroctocog alfa                                                                                                                                                                                                                                                             | 14/06/2018 | n/a |                        | PRAC Recommendation - maintenance |
| IA/0025/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material | 16/04/2018 | n/a |                        |                                   |
| IB/0022             | B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a biological/immunological AS is increased/decreased without process change (e.g. duplication of line)                                                                                                                 | 28/03/2018 | n/a |                        |                                   |
| IB/0023             | B.I.b.1.i - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Where there is no monograph in the European/National Ph. for the AS, a change in specification from in-house to a non- official/third country Ph.                                                       | 22/02/2018 | n/a |                        |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0019             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 07/02/2018   | n/a        |                   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|-----------------------------------|
| N/0020              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 30/01/2018   | 07/12/2018 | PL                |                                   |
| PSUSA/10451 /201706 | Periodic Safety Update EU Single assessment - efmoroctocog alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 11/01/2018   | n/a        |                   | PRAC Recommendation - maintenance |
| IB/0018             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 16/11/2017   | 07/12/2018 | SmPC and Annex II |                                   |
| II/0016/G           | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material | 16/11/2017   | n/a        |                   |                                   |

<div style=\"page-break-after: always\"></div>

| A31/0006   | Pursuant to Article 31 of Directive 2001/83/EC, Germany initiated a procedure on 6 July 2016 based                                      | 14/09/2017   | 16/11/2017   | SmPC and PL   | Please refer to the assessment report: human coagulation factor VIII - EMEA/H/A-31/1448   |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-------------------------------------------------------------------------------------------|
| IB/0015    | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB | 06/07/2017   | n/a          |               |                                                                                           |

<div style=\"page-break-after: always\"></div>

| PSUSA/10451 /201612   | Periodic Safety Update EU Single assessment - efmoroctocog alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 06/07/2017   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| II/0012/G             | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 22/06/2017   | n/a   |                                     |
| IB/0014               | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                             | 27/04/2017   | n/a   |                                     |
| II/0010               | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                      | 23/02/2017   | n/a   |                                     |
| IB/0011               | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                                     | 16/01/2017   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

| II/0008/G           | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a   | 15/12/2016   | n/a        |           |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------|-----------------------------------|
| PSUSA/10451 /201605 | Periodic Safety Update EU Single assessment - efmoroctocog alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 01/12/2016   | n/a        |           | PRAC Recommendation - maintenance |
| N/0009              | Update of the QRD code content. Minor change in labelling or package leaflet not                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 26/10/2016   | 31/05/2017 | Labelling |                                   |

<div style=\"page-break-after: always\"></div>

|           | connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                 |            |            |                        |                                                                                                     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------|
| IB/0004/G | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 05/07/2016 | 31/05/2017 | SmPC                   |                                                                                                     |
| IB/0003   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                   | 07/06/2016 | n/a        |                        |                                                                                                     |
| IAIN/0005 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                              | 02/06/2016 | n/a        |                        |                                                                                                     |
| T/0002    | Transfer of the Marketing Aughorisation Transfer of Marketing Authorisation                                                                                                                                     | 24/02/2016 | 23/03/2016 | SmPC, Labelling and PL | Transfer of the Marketing Aughorisation from Biogen Idec Ltd to Swedish Orphan Biovitrum AB (publ). |
| IAIN/0001 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                 | 09/12/2015 | n/a        |                        |                                                                                                     |